BBIO oral infigratinib shows benefits in PROPEL 3 phase 3
TradeXchange says BBIO’s oral infigratinib showed meaningful benefits within 52 weeks in children with achondroplasia in the Phase 3 PROPEL 3 trial.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.